News from merck A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jul 08, 2019, 07:30 ET Skyhawk Therapeutics Announces Collaboration Agreement with Merck to Discover and Develop Novel Small Molecules that Modulate RNA Splicing

Skyhawk Therapeutics, Inc. (Skyhawk) today announced that it has entered a strategic collaboration with Merck, known as MSD outside the United States and Canada, to discover, develop and...


Mar 18, 2019, 08:00 ET New Treatment Option Now Available in Canada for Newly Diagnosed Patients with Advanced Lung Cancer

KEYTRUDA® (pembrolizumab) in Combination with Pemetrexed and Platinum Chemotherapy Reduced the Risk of Death by Half Compared to Chemotherapy Alone Every day, approximately 78 Canadians are diagnosed ...


Jan 24, 2019, 08:00 ET Merck Grants Exclusive License to Vertex for Two DNA Damage Response Inhibitors

Not intended for UK- or US-based media Exclusive license grants Vertex one clinical and one pre-clinical DNA-PK inhibitor for use in gene-editing applications in six specific genetic disease areas...


Nov 19, 2018, 17:09 ET Merck Canada reaffirms its commitment to CQDM with a $3.5M contribution to sustain innovation in life sciences

MONTREAL, Nov. 19, 2018 /CNW Telbec/ - CQDM is delighted to announce that Merck Canada, a founding member of the consortium, is renewing its commitment with a $3.5M contribution to support the...


Oct 11, 2018, 13:30 ET Global Survey and Documentary Film Expose Emotional Impact of Multiple Sclerosis

Not intended for U.S media Merck-sponsored survey developed in collaboration with IACO and Eurocarers reveals lifelong effects of caring for a loved one with MS #MSInsideOut documentary film,...


Oct 01, 2018, 08:58 ET Dragonfly Therapeutics Announces New Multi-Target Collaboration with Merck to Use Dragonfly's Proprietary TriNKET™ Platform to Develop Novel Drug Candidates for Patients with Solid Tumors

Dragonfly Therapeutics, Inc. ("Dragonfly"), today announced a strategic collaboration with Merck, known as MSD outside the United States and Canada, through a subsidiary, to discover, develop and...


Jun 04, 2018, 09:32 ET Merck Presents Updated Clinical Results for Bifunctional Immunotherapy M7824 at ASCO 2018

ASCO Abstract # M7824 (TGF-ß trap/anti-PD-L1): 3007, 9017, 2566, TPS3130; Tepotinib (c-Met kinase inhibitor): 9082, 9016; M2698 (dual p70S6k/Akt inhibitor): 2584; M6620 (ATR inhibitor): 2549; M3814...


Jun 03, 2018, 08:30 ET Merck Presents Update on Tepotinib in Advanced Lung Cancer at ASCO 2018

/NOT INTENDED FOR UK- OR US-BASED MEDIA/ DARMSTADT, Germany, June 3, 2018 /CNW/ - ASCO Abstract # Tepotinib (c-Met kinase inhibitor): 9082, 9016; M7824 (TGF-ß trap/anti-PD-L1): 3007, 9017, 2566;...


Mar 27, 2018, 08:40 ET Merck Receives Fast-Track Designation for Tepotinib in Non-Small Cell Lung Cancer in Japan

/NOT INTENDED FOR UK- OR US-BASED MEDIA/ Japanese Ministry of Health, Labour and Welfare Grants SAKIGAKE designation for tepotinib, Merck's investigational highly selective c-Met receptor tyrosine...


Jan 18, 2018, 04:00 ET The Consumer Health of Merck Walks the Talk with its WE100 Movement

DARMSTADT, Germany, Jan. 18, 2018 /CNW/ - Consumer Health accelerates its WE100® movement by launching new partnership programme with pharmacists in the UK on enabling 100 years of healthy living...


Dec 21, 2017, 14:04 ET FDA Grants Breakthrough Therapy Designation for Avelumab in Combination with INLYTA® in Advanced Renal Cell Carcinoma

Second Breakthrough Therapy Designation for avelumab in hard-to-treat cancer Renal cell carcinoma, the most common form of kidney cancer, has a poor prognosis in advanced stage[1],[2] Javelin Renal...


Nov 07, 2017, 04:00 ET Merck's Consumer Health Leads Debate on Preparing Gen Z for 100 Healthy Years

New whitepaper from Consumer Health business shines light on preparing the young generation for living 100 healthy years Whitepaper focuses on the importance to adopt good health habits early on to...


Aug 08, 2017, 05:57 ET NICE Recommends Erbitux® in Combination with Platinum-Based Chemotherapy for the Treatment of Recurrent and/or Metastatic Head and Neck Cancer in the Oral Cavity

DARMSTADT, Germany, Aug. 8, 2017 /CNW/ - Not intended for U.K./U.S. based media Decision secures access to Erbitux® for new patients in England with oral cavity tumors All patients currently...


Jul 10, 2017, 07:00 ET PDS Biotechnology Corp. Announces Clinical Collaboration with Merck to Evaluate Combination of Versamune® PDS0101 and KEYTRUDA® (pembrolizumab) for Metastatic Head and Neck Cancer

PDS Biotechnology Corporation ("PDS"), a private clinical stage immuno-oncology company developing novel immunotherapies, has entered a clinical trial collaboration agreement with a subsidiary of...


May 19, 2017, 04:00 ET 100 Healthy Years - Are Kids Prepared?

Merck Consumer Health's Annual Debate: global expert discussion on how to prepare children to live 100 healthy years Global study of the Economist Intelligence Unit: today's children will be less...


May 10, 2017, 10:01 ET European Commission Grants Approval for Merck's New Pergoveris® Pen for Fertility Treatment

/NOT INTENDED FOR U.S. AND UK BASED MEDIA/ With this approval, Pergoveris® becomes the first product with a combination of FSH and LH hormones in a ready-to-use liquid version The new pre-filled...


Mar 10, 2017, 05:32 ET New Merck Technology Aims to Further Optimize Embryo Incubation and Assessment

DARMSTADT, Germany, March 10, 2017 /CNW/ - Merck integrates innovative Eeva® Test with Geri™ incubation platform, bringing individualized incubation and outcome prediction together Geri™ humidity...


Feb 24, 2017, 08:32 ET Merck Receives Positive CHMP Opinion for New Pergoveris® Fertility Pen

Not intended for U.S. and UK based media Ready-to-use pre-filled pen provides a convenient treatment option for patients Simplified injection device for self-administration comes in multiple doses,...


Jan 20, 2017, 06:01 ET Merck and Genea Open Centre of Excellence for Fertility

Not intended for U.S. based media Merck is broadening its efforts to support ART clinics to achieve excellence for patients Through leading edge education and training, the Centre of Excellence aims...


Dec 06, 2016, 09:00 ET Merck's Consumer Health Business Drives Consumer-Centric, Purposeful Innovation

DARMSTADT, Germany, Dec. 6, 2016 /CNW/ - Innovation and digital presence identified as main drivers of successful engagement with consumers and healthcare professionals Merck, a leading science and...


Oct 10, 2016, 02:49 ET Merck Announces Recipients of Third Annual €1 Million 'Grant for Oncology Innovation' Award

Not intended for UK- or UK-based media Grant established by Merck recognizes pioneering research in personalized treatment of solid tumors Winners selected by internationally renowned oncologists...


Oct 04, 2016, 04:15 ET Merck Launches Two Innovative Technologies to Support Couples on Their Fertility Treatment Journey

Not intended for U.S. based media Gavi™ allows freezing of oocytes and embryos at key stages Geri™ medium supports undisturbed embryo growth Launches in line with Merck's healthcare strategy to...


Sep 28, 2016, 03:24 ET Merck to Present New Research Focused on Hard-to-Treat Cancers at ESMO 2016

DARMSTADT, Germany, Sept. 28, 2016 /CNW/ - Not intended for UK- or US-based media ESMO Abstract # Avelumab: 777PD, 775PD, 1154P, 842TiP, 844TiP; Erbitux: 527P, 491P, 967P, 994P; Tepotinib: 1257P,...


Sep 13, 2016, 03:15 ET Merck's Consumer Health Business Presents New Purpose to Help Prepare Society for 100 Healthy Years

DARMSTADT, Germany, Sept. 13, 2016 /CNW/ - "WE100" movement will promote activities to prepare society for 100 healthy years across generations Merck, a leading science and technology company,...


Sep 07, 2016, 08:34 ET Aralez Acquires United States And Canadian Rights To ZONTIVITY From Merck

Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ), a global specialty pharmaceutical company, today announced that it acquired the U.S. and Canadian rights to ZONTIVITY® (vorapaxar), pursuant to...